EP4164607A4 - METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA USING FENOTEROL HYDROBROBROM, A β2-ADRENERGIC RECEPTOR AGONIST, AND ITS DERIVATIVES - Google Patents

METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA USING FENOTEROL HYDROBROBROM, A β2-ADRENERGIC RECEPTOR AGONIST, AND ITS DERIVATIVES Download PDF

Info

Publication number
EP4164607A4
EP4164607A4 EP21822599.3A EP21822599A EP4164607A4 EP 4164607 A4 EP4164607 A4 EP 4164607A4 EP 21822599 A EP21822599 A EP 21822599A EP 4164607 A4 EP4164607 A4 EP 4164607A4
Authority
EP
European Patent Office
Prior art keywords
hydrobrobrom
fenoterol
derivatives
compositions
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21822599.3A
Other languages
German (de)
French (fr)
Other versions
EP4164607A1 (en
Inventor
Andrei V. Tkatchenko
Tatiana V. TKATCHENKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP4164607A1 publication Critical patent/EP4164607A1/en
Publication of EP4164607A4 publication Critical patent/EP4164607A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP21822599.3A 2020-06-11 2021-06-09 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA USING FENOTEROL HYDROBROBROM, A β2-ADRENERGIC RECEPTOR AGONIST, AND ITS DERIVATIVES Withdrawn EP4164607A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063037891P 2020-06-11 2020-06-11
PCT/US2021/036614 WO2021252626A1 (en) 2020-06-11 2021-06-09 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA WITH FENOTEROL HYDROBROMIDE, A β2- ADRENERGIC RECEPTOR AGONIST, AND DERIVATIVES THEREOF

Publications (2)

Publication Number Publication Date
EP4164607A1 EP4164607A1 (en) 2023-04-19
EP4164607A4 true EP4164607A4 (en) 2024-07-10

Family

ID=78846491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21822599.3A Withdrawn EP4164607A4 (en) 2020-06-11 2021-06-09 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA USING FENOTEROL HYDROBROBROM, A β2-ADRENERGIC RECEPTOR AGONIST, AND ITS DERIVATIVES

Country Status (7)

Country Link
EP (1) EP4164607A4 (en)
JP (1) JP2023530679A (en)
KR (1) KR20230051152A (en)
CN (1) CN116194094A (en)
CA (1) CA3182397A1 (en)
IL (1) IL298974A (en)
WO (1) WO2021252626A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020251926A1 (en) * 2019-06-10 2020-12-17 Jenivision Inc. Methods and formulations for treating vision disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1731101A (en) * 1999-12-07 2001-06-18 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
TW200815054A (en) * 2006-06-19 2008-04-01 Otsuka Pharma Co Ltd Methods of using a thiazole derivative
WO2008022038A1 (en) * 2006-08-10 2008-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
WO2010125416A1 (en) * 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US9456997B2 (en) * 2010-08-26 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of β1-adrenergic receptors for the treatment of pediatric heart failure
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
GB2513297A (en) * 2013-03-08 2014-10-29 Univ Leicester Methods
JP2017507959A (en) * 2014-03-13 2017-03-23 ボドール ラボラトリーズ， インコーポレイテッド Use of selected anticholinergic zwitterions
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020251926A1 (en) * 2019-06-10 2020-12-17 Jenivision Inc. Methods and formulations for treating vision disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021252626A1 *
TATIANA V. TKATCHENKO: "Analysis of genetic networks regulating refractive eye development in collaborative cross progenitor strain mice reveals new genes and pathways underlying human myopia", BMC MEDICAL GENOMICS, vol. 12, no. 1, 30 July 2019 (2019-07-30), London UK, XP093163579, ISSN: 1755-8794, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s12920-019-0560-1/fulltext.html> DOI: 10.1186/s12920-019-0560-1 *
TATIANA V. TKATCHENKO: "Gene expression in response to optical defocus of opposite signs reveals bidirectional mechanism of visually guided eye growth", PLOS BIOLOGY, vol. 16, no. 10, 9 October 2018 (2018-10-09), US, pages e2006021, XP093163623, ISSN: 1545-7885, DOI: 10.1371/journal.pbio.2006021 *
TATIANA V. TKATCHENKO: "Pharmacogenomic Approach to Antimyopia Drug Development: Pathways Lead the Way", TRENDS IN PHARMACOLOGICAL SCIENCES., vol. 40, no. 11, 1 November 2019 (2019-11-01), GB, pages 833 - 852, XP093163629, ISSN: 0165-6147, DOI: 10.1016/j.tips.2019.09.009 *

Also Published As

Publication number Publication date
WO2021252626A1 (en) 2021-12-16
IL298974A (en) 2023-02-01
EP4164607A1 (en) 2023-04-19
CA3182397A1 (en) 2021-12-16
KR20230051152A (en) 2023-04-17
JP2023530679A (en) 2023-07-19
CN116194094A (en) 2023-05-30

Similar Documents

Publication Publication Date Title
MA55214A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
EP3792298A4 (en) SOLID DISPERSION, METHOD FOR THE PREPARATION THEREOF, EXTENDED CHAIN POLYURETHANE USING THE SAME, AND EPOXY RESIN COMPOSITION COMPRISING THE SAME
EP3828206A4 (en) EFFICIENT METHOD FOR MAKING AN ANTIBODY-DRUG CONJUGATE
EP3870170A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISORDERS
EP3793566A4 (en) COMPOSITIONS AND METHODS FOR REDUCING SPLICING DEFECTS AND TREATING RNA DOMINANCE DISORDERS
EP3776430A4 (en) SYSTEM AND METHOD FOR DEVELOPING A DECENTRALIZED APPLICATION BASED ON A BLOCKCHAIN
EP3752632A4 (en) RNA MODIFIED GUIDES FOR GENOME EDITING USING CRISPR
MA30339B1 (en) AZOLOPYRIMIDINES INHIBITORS OF CANNABINOID RECEPTOR ACTIVITY 1
EP3839678A4 (en) MACHINE-TOOL, ENTRY ASSISTANCE PROCESS FOR MACHINE-TOOL AND PROGRAM FOR MACHINE-TOOL
YU17397A (en) Mesylate trihydrate of 5-(2-(4-(1,2-benzisthiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
EP4114400A4 (en) METHODS AND COMPOSITIONS FOR ADMINISTRATION OF MODIFIED LYMPHOCYTE AGGREGATES
EP4149552A4 (en) COMPOSITIONS AND METHODS FOR INCREASING THE EFFECTIVENESS OF A DRUG
EP3743091A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANGIOGENIC DISORDERS USING ANTI-VEGF AGENTS
EP3813793A4 (en) COMPOSITION FOR TREATING OCULAR HYPEREMIA AND METHOD FOR TREATING OCULAR HYPEREMIA USING IT
EP3978683A4 (en) OIL RESISTANT AGENT FOR PAPER
EP3900932A4 (en) METHOD FOR MAKING A LAMINATED STEEL PLATE, DEVICE FOR MAKING A LAMINATED STEEL PLATE, AND CURING COMPOSITION USED THEREOF
FR3015870B1 (en) DEVICE FOR MAKE-UP BY TRANSFERRING KERATINIC MATERIALS.
EP3737668C0 (en) METHOD FOR SOLUBILIZING 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE
EP3815912A4 (en) METHOD FOR PRODUCING RELIEF BY MEANS OF DIGITAL PRINTING AND DIGITAL PRINTING MACHINE
EP4164607A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA USING FENOTEROL HYDROBROBROM, A β2-ADRENERGIC RECEPTOR AGONIST, AND ITS DERIVATIVES
EP3976612A4 (en) NEW COMPOUNDS FOR JANUS KINASE 1 INHIBITION
EP4164640A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA WITH BERBERINE, A BERBERIDACEOUS ALKALOID, AND DERIVATIVES THEREOF
EP3930647A4 (en) INSERT DEVICE FOR GLAUCOMA DEVICE
EP3928951A4 (en) MOLDING ASSIST DEVICE FOR INJECTION MOLDING MACHINE
EP3866799A4 (en) COMPOSITIONS AND METHODS FOR TREATING EHLERS-DANLOS DISEASE AND ASSOCIATED DISORDERS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230606

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009000000

Ipc: A61K0031137000

A4 Supplementary search report drawn up and despatched

Effective date: 20240607

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/10 20060101ALI20240603BHEP

Ipc: A61K 9/00 20060101ALI20240603BHEP

Ipc: A61K 31/137 20060101AFI20240603BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250103